BAC B.V. Completes Feasibility Study in Providing Unique Selective Ligands For Genmab A/S's UniBody(R) Platform

NAARDEN, The Netherlands--(BUSINESS WIRE)--BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it successfully completed a feasibility study in its collaboration with Genmab A/S (Copenhagen, Denmark), an international biotechnology company developing human antibody therapeutics for the potential treatment of cancer. Under this collaboration, BAC developed CaptureSelect® custom affinity ligands for use in monitoring Genmab UniBody® drug candidates in preclinical studies and clinical trials and delivered positive results from the initial feasibility study.